PT3341368T - Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 - Google Patents
Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5Info
- Publication number
- PT3341368T PT3341368T PT167572338T PT16757233T PT3341368T PT 3341368 T PT3341368 T PT 3341368T PT 167572338 T PT167572338 T PT 167572338T PT 16757233 T PT16757233 T PT 16757233T PT 3341368 T PT3341368 T PT 3341368T
- Authority
- PT
- Portugal
- Prior art keywords
- novel
- aromatic ring
- ring substituted
- bicyclic aromatic
- nucleoside analogues
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940127073 nucleoside analogue Drugs 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15184011 | 2015-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3341368T true PT3341368T (pt) | 2021-12-09 |
Family
ID=54065259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167572338T PT3341368T (pt) | 2015-09-07 | 2016-08-25 | Novos análogos de nucleósidos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US10653711B2 (pt) |
| EP (3) | EP3974428A1 (pt) |
| JP (3) | JP6917978B2 (pt) |
| KR (1) | KR102716092B1 (pt) |
| CN (2) | CN114057815B (pt) |
| AR (1) | AR105820A1 (pt) |
| AU (4) | AU2016311295B2 (pt) |
| BR (2) | BR122023020317A2 (pt) |
| CA (1) | CA2992688A1 (pt) |
| CL (1) | CL2018000510A1 (pt) |
| CO (1) | CO2018002063A2 (pt) |
| CY (1) | CY1125359T1 (pt) |
| DK (1) | DK3341368T3 (pt) |
| EA (1) | EA201890573A1 (pt) |
| ES (1) | ES2901972T3 (pt) |
| HR (1) | HRP20211997T1 (pt) |
| HU (1) | HUE057312T2 (pt) |
| IL (3) | IL311843A (pt) |
| LT (1) | LT3341368T (pt) |
| MA (1) | MA42678B1 (pt) |
| MD (1) | MD3341368T2 (pt) |
| MX (2) | MX392554B (pt) |
| MY (1) | MY198472A (pt) |
| NZ (2) | NZ740528A (pt) |
| PE (2) | PE20180929A1 (pt) |
| PH (2) | PH12018500425B1 (pt) |
| PL (1) | PL3341368T3 (pt) |
| PT (1) | PT3341368T (pt) |
| RS (1) | RS62698B1 (pt) |
| SG (1) | SG10202003775VA (pt) |
| SI (1) | SI3341368T1 (pt) |
| SM (1) | SMT202100725T1 (pt) |
| TN (1) | TN2018000043A1 (pt) |
| TW (3) | TWI870767B (pt) |
| WO (1) | WO2017032840A1 (pt) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| EA201892031A1 (ru) * | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5 |
| CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| ES2872003T3 (es) | 2016-09-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Inhibidores espirobicíclicos de la interacción de menina-MLL |
| CN109715634B (zh) | 2016-09-14 | 2022-09-27 | 詹森药业有限公司 | Menin-mll相互作用的稠合二环抑制剂 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019006414A2 (pt) | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| GB201700526D0 (en) * | 2017-01-12 | 2017-03-01 | Univ Of Hull | Therapeutic use |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| PT3665179T (pt) | 2017-08-09 | 2021-09-10 | Prelude Therapeutics Inc | Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| WO2019084470A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| JP2021505583A (ja) * | 2017-12-05 | 2021-02-18 | エンジェクス ファーマシューティカル インコーポレイテッド | Ｐｍｒｔ５阻害剤としての複素環式化合物 |
| WO2019110734A1 (en) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| GEP20227359B (en) | 2017-12-13 | 2022-03-10 | Lupin Ltd | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| PL3765461T3 (pl) * | 2018-03-14 | 2024-03-04 | Prelude Therapeutics, Incorporated | Selektywne inhibitory białkowej metylotranserazy argininy 5 (prmt5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| EP3833355A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| US11993602B2 (en) * | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12435088B2 (en) | 2018-12-21 | 2025-10-07 | Memorial Sloan-Kettering Cancer Center | Salicyl-adenosinemonosulfamate analogs and uses thereof |
| CN109400545B (zh) * | 2018-12-24 | 2022-03-25 | 济南大学 | 一种精氨酸甲基转移酶5抑制剂及其应用 |
| CN109369507A (zh) * | 2018-12-26 | 2019-02-22 | 重庆市碚圣医药科技股份有限公司 | 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法 |
| BR112021015796A2 (pt) * | 2019-02-13 | 2021-10-13 | Prelude Therapeutics, Incorporated | Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5) |
| WO2020190073A1 (ko) * | 2019-03-20 | 2020-09-24 | 한국화학연구원 | 신규한 아졸로피리미딘 헤테로고리 화합물을 유효 성분으로 함유하는 약제학적 조성물 |
| US20220194949A1 (en) * | 2019-03-25 | 2022-06-23 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| EP3946352A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| US20220152072A1 (en) * | 2019-04-05 | 2022-05-19 | Prelude Therapeutics, Incorporated | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) |
| CA3141855A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| PT3980417T (pt) | 2019-06-10 | 2023-12-28 | Lupin Ltd | Inibidores de prmt5 |
| CR20220012A (es) | 2019-06-12 | 2022-03-11 | Janssen Pharmaceutica Nv | Nuevos intermedios espirobiciclicos |
| MX2022003340A (es) | 2019-09-18 | 2022-06-14 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). |
| JP2022553077A (ja) * | 2019-10-21 | 2022-12-21 | アクセント・セラピューティクス・インコーポレイテッド | Ｍｅｔｔｌ３モジュレーター |
| CN114599361B (zh) * | 2019-10-22 | 2024-07-09 | 印度鲁宾有限公司 | Prmt5抑制剂的药物组合物 |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| US20230066014A1 (en) * | 2019-12-03 | 2023-03-02 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| MX2022007652A (es) | 2019-12-19 | 2022-09-23 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal. |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
| WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| CN112645875A (zh) * | 2020-12-09 | 2021-04-13 | 深圳海王医药科技研究院有限公司 | 一种盐酸丙卡特罗杂质的制备方法 |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| CN116003339B (zh) * | 2022-12-01 | 2024-06-28 | 南京师范大学 | 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| CA2476683C (en) | 2002-02-19 | 2011-11-01 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US7144674B2 (en) * | 2002-03-20 | 2006-12-05 | Sumitomo Chemical Company, Limited | Positive resist composition |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| US20060167241A1 (en) | 2003-07-15 | 2006-07-27 | Mitsui Chemicals, Inc. | Method for synthesizing cyclic bisdinucleoside |
| CA2548283A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| EA201270661A1 (ru) | 2009-12-18 | 2013-06-28 | Президент Энд Феллоуз Оф Гарвард Колледж | УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US9029343B2 (en) | 2010-12-03 | 2015-05-12 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| KR20130124959A (ko) * | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법 |
| WO2012083170A1 (en) | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| ES2587512T3 (es) | 2011-04-04 | 2016-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Derivados de 2'-O-aminooximetil nucleósido para su uso en la síntesis y modificación de nucleósidos, nucleótidos y oligonucleótidos |
| EP2771012A4 (en) | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | NEW CONNECTIONS |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| JP2016505000A (ja) * | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| WO2014145214A2 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP6603712B2 (ja) | 2014-07-01 | 2019-11-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物 |
| KR20170119705A (ko) | 2015-02-24 | 2017-10-27 | 화이자 인코포레이티드 | 항암제로서 유용한 치환된 뉴클레오시드 유도체 |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| WO2017153186A1 (en) | 2016-03-10 | 2017-09-14 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019006414A2 (pt) * | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| WO2019110734A1 (en) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
-
2016
- 2016-08-24 TW TW112102610A patent/TWI870767B/zh active
- 2016-08-24 TW TW110127686A patent/TWI791251B/zh active
- 2016-08-24 TW TW105126988A patent/TWI730980B/zh active
- 2016-08-25 HR HRP20211997TT patent/HRP20211997T1/hr unknown
- 2016-08-25 EP EP21199207.8A patent/EP3974428A1/en active Pending
- 2016-08-25 NZ NZ740528A patent/NZ740528A/en unknown
- 2016-08-25 MY MYPI2018000274A patent/MY198472A/en unknown
- 2016-08-25 SI SI201631402T patent/SI3341368T1/sl unknown
- 2016-08-25 MX MX2018002326A patent/MX392554B/es unknown
- 2016-08-25 CN CN202111120182.2A patent/CN114057815B/zh active Active
- 2016-08-25 PE PE2018000306A patent/PE20180929A1/es unknown
- 2016-08-25 NZ NZ779003A patent/NZ779003A/en unknown
- 2016-08-25 PH PH1/2018/500425A patent/PH12018500425B1/en unknown
- 2016-08-25 WO PCT/EP2016/070097 patent/WO2017032840A1/en not_active Ceased
- 2016-08-25 PL PL16757233T patent/PL3341368T3/pl unknown
- 2016-08-25 AR ARP160102600A patent/AR105820A1/es active IP Right Grant
- 2016-08-25 MA MA42678A patent/MA42678B1/fr unknown
- 2016-08-25 US US15/755,475 patent/US10653711B2/en active Active
- 2016-08-25 PE PE2022000450A patent/PE20221629A1/es unknown
- 2016-08-25 CN CN201680048987.1A patent/CN107922413B/zh active Active
- 2016-08-25 RS RS20211526A patent/RS62698B1/sr unknown
- 2016-08-25 SM SM20210725T patent/SMT202100725T1/it unknown
- 2016-08-25 ES ES16757233T patent/ES2901972T3/es active Active
- 2016-08-25 EA EA201890573A patent/EA201890573A1/ru unknown
- 2016-08-25 EP EP16757233.8A patent/EP3341368B1/en active Active
- 2016-08-25 PT PT167572338T patent/PT3341368T/pt unknown
- 2016-08-25 TN TNP/2018/000043A patent/TN2018000043A1/en unknown
- 2016-08-25 KR KR1020187007810A patent/KR102716092B1/ko active Active
- 2016-08-25 BR BR122023020317-8A patent/BR122023020317A2/pt not_active Application Discontinuation
- 2016-08-25 CA CA2992688A patent/CA2992688A1/en active Pending
- 2016-08-25 LT LTEPPCT/EP2016/070097T patent/LT3341368T/lt unknown
- 2016-08-25 JP JP2018510334A patent/JP6917978B2/ja active Active
- 2016-08-25 IL IL311843A patent/IL311843A/en unknown
- 2016-08-25 AU AU2016311295A patent/AU2016311295B2/en active Active
- 2016-08-25 BR BR112018003595-5A patent/BR112018003595B1/pt active IP Right Grant
- 2016-08-25 DK DK16757233.8T patent/DK3341368T3/da active
- 2016-08-25 PH PH1/2021/552054A patent/PH12021552054A1/en unknown
- 2016-08-25 SG SG10202003775VA patent/SG10202003775VA/en unknown
- 2016-08-25 MD MDE20180642T patent/MD3341368T2/ro unknown
- 2016-08-25 EP EP23162887.6A patent/EP4219496A1/en active Pending
- 2016-08-25 HU HUE16757233A patent/HUE057312T2/hu unknown
-
2018
- 2018-02-21 IL IL257664A patent/IL257664B/en active IP Right Grant
- 2018-02-23 MX MX2022005182A patent/MX2022005182A/es unknown
- 2018-02-26 CO CONC2018/0002063A patent/CO2018002063A2/es unknown
- 2018-02-26 CL CL2018000510A patent/CL2018000510A1/es unknown
-
2020
- 2020-03-20 US US16/825,024 patent/US11318157B2/en active Active
-
2021
- 2021-01-20 AU AU2021200345A patent/AU2021200345B2/en active Active
- 2021-04-21 IL IL282537A patent/IL282537A/en unknown
- 2021-07-20 JP JP2021120042A patent/JP7720732B2/ja active Active
-
2022
- 2022-01-04 CY CY20221100008T patent/CY1125359T1/el unknown
- 2022-03-09 US US17/690,587 patent/US11883367B2/en active Active
- 2022-08-11 AU AU2022215260A patent/AU2022215260B2/en active Active
-
2023
- 2023-03-21 US US18/187,463 patent/US20230330127A1/en not_active Abandoned
- 2023-10-27 JP JP2023184701A patent/JP2024012405A/ja not_active Withdrawn
-
2024
- 2024-03-28 AU AU2024202052A patent/AU2024202052A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282537A (en) | Novel 6–6 bicyclic aromatic ring-converted nucleoside analogs for use as PRMT5 inhibitors | |
| IL261559B (en) | Converted nucleoside analogs for use as prmt5 inhibitors | |
| IL288519B1 (en) | inhibitors of ret | |
| IL286428A (en) | Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases | |
| ZA201800480B (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| ZA201801032B (en) | Bicyclic compounds as atx inhibitors | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| IL255570A (en) | Bicyclic compounds as atx inhibitors | |
| IL255511B (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| EP3212657A4 (en) | Methods of preparing substituted nucleoside analogs | |
| IL249456A0 (en) | Methods for preparing analogues of modified nucleotides | |
| IL265718B (en) | Novel modified carbonucleoside analogs with monocyclic and cyclic ring systems as prmt5 inhibitors | |
| HUE053463T2 (hu) | Pirrolopirimidin vegyületek, amelyek használhatók JAK inhibitorokként | |
| IL255357A0 (en) | bicyclic compounds | |
| IL256226A (en) | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors | |
| HK40067051A (zh) | 作为prmt5抑制剂的、新颖6-6二环芳环取代的核苷 | |
| ZA201806016B (en) | Substituted nucleoside analogues for use as prmt5 inhibitors |